Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Imunon, Inc. - Common Stock (NQ:IMNN)

1.995 -0.025 (-1.24%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Imunon, Inc. - Common Stock

News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum: Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for June 11th-12th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON Announces Strategic Investment in Transomic Technologies
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon Appoints James E. Dentzer to its Board of Directors
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon Reports Partial Results from Ongoing Non-human Primate Study
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.